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Consumption of long-chain n-3 PUFA, particularly DHA, has been shown to improve cardiovascular risk factors but the intake required to achieve
benefits is unclear. We sought to determine the relationship between DHA intake, increases in erythrocyte DHA content and changes in blood
lipids. A total of sixty-seven subjects (thirty-six male, thirty-one female, mean age 53 years) with fasting serum TAG $ 1·1mmol/l and
BMI . 25 kg/m2 completed a 12-week, randomized, double-blind, placebo-controlled parallel intervention. Subjects consumed 2, 4 or 6 g/d of
DHA-rich fish oil (26% DHA, 6% EPA) or a placebo (Sunola oil). Fasting blood lipid concentrations and fatty acid profiles in erythrocyte mem-
branes were assessed at baseline and after 6 and 12 weeks. For every 1 g/d increase in DHA intake, there was a 23% reduction in TAG (mean
baseline concentration 1·9 (SEM 0·1) mmol/l), 4·4% increase in HDL-cholesterol and 7·1% increase in LDL-cholesterol. Erythrocyte DHA content
increased in proportion to the dose of DHA consumed (r 0·72, P,0·001) and the increase after 12 weeks was linearly related to reductions in TAG
(r 20·38, P,0·01) and increases in total cholesterol (r 0·39, P,0·01), LDL-cholesterol (r 0·33, P,0·01) and HDL-cholesterol (r 0·30, P¼0·02).
The close association between incorporation of DHA in erythrocytes and its effects on serum lipids highlights the importance of erythrocyte DHA
as an indicator of cardiovascular health status.
Lipids: n-3 PUFA: Docosahexaenoic acid
Fish oil supplementation increases the relative proportion of
the long-chain (LC) n-3 PUFA, EPA and DHA, in erythrocyte
membranes(1). DHA, in particular, is incorporated on the
inside of the erythrocyte membrane and is present for the
life of the cell(1,2). This provides a readily assessable marker
of long-term accumulation and potential bioavailability in
other tissues(3). Increased incorporation of LC n-3 PUFA in
erythrocyte membranes is associated with reduced CVD mor-
bidity and mortality(4). This relationship forms the basis of the
Omega-3 Index(4), a concept promoted as a relatively simple
means of predicting the likelihood of CVD outcomes. How-
ever, it may also be possible to relate erythrocyte LC n-3
PUFA to CVD risk factors rather than morbidity and mor-
tality, thereby allowing for the prediction of improvement in
risk factors resulting from dietary intervention.
A high TAG level in fasting blood is an independent
risk factor for CVD(5,6). LC n-3 PUFA consumption
lowers blood TAG levels in healthy subjects(7–11) but the opti-
mal dose for TAG reduction is not clear. While the American
Heart Association recommends consuming 2–4 g n-3 PUFA/d
for TAG reduction in individuals with hypertriacylglycerolae-
mia(12), a recent study reported a 23% reduction in fasting
TAG in normolipidaemics with only 0·94 g DHA/d, indicating
that lower doses of fish oil may also be effective for TAG
reduction(10). The TAG-lowering effect of fish oil has been
variously attributed to EPA(13) or equally to EPA and
DHA(11). Numerous studies with DHA-rich oil have shown
reductions in TAG(9,10,14,15), and the addition of EPA in a
DHA-rich supplement was previously found to have no
additional effect on TAG-lowering(16). However, there have
been few well-designed studies aimed at establishing a
dose–response relationship between DHA intake and TAG
reduction. Previous studies used small sample sizes in their
intervention(17–20), dietary restriction(18) or participants with
extreme hypertriacylglycerolaemia (up to 13·45mmol/l)(17).
The purpose of the present study was to establish a dose–
response relationship between moderate levels of DHA-rich
fish oil supplementation and changes in both erythrocyte
DHA content and blood lipids.
Methods
A randomized, double-blind, placebo-controlled, parallel
design dose–response supplementation trial of 12 weeks dur-
ation was undertaken. The study was approved by the Human
Research Ethics Committees of the University of Adelaide and
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the University of South Australia (Adelaide, Australia) and
conducted according to Good Clinical Research Practice
Guidelines. Written informed consent was obtained from all
participants prior to commencement.
Subjects
Seventy-five non-smoking volunteers with a BMI . 25 kg/m2
and fasting serum TAG $ 1·1mmol/l were recruited for
the study. Participants taking lipid-lowering, blood-thinning
or antihypertensive medication, fish oil supplements or
consuming more than one serving of fish per week were
excluded.
Study design
Subjects were block-matched into four groups which were
stratified according to fasting serum TAG concentration. The
groups were then randomized to consume six 1 g oil cap-
sules/d comprising either 0, 2, 4 or 6 £ 1 g capsules of
DHA-rich fish oil containing 26% DHA and 6% EPA
(NuMega Ingredients, Victoria, Australia) with the balance
of the capsules made up of 1 g Sunola oil capsules (NuMega
Ingredients). The 2, 4 and 6 g/d doses provided 0·52, 1·04
and 1·56 g DHA/d, respectively. Subjects visited the research
clinic on two consecutive mornings at baseline, week 6 and
week 12 after an overnight (10–12 h) fast. Height and
weight were measured and blood was collected by venepunc-
ture on each occasion.
Assessment of erythrocyte fatty acid profiles
The relative proportions of LC n-3 PUFA in erythrocytes were
determined as described previously(21). Briefly, blood samples
were collected in EDTA tubes and erythrocytes were isolated
within 2 h by centrifugation, washed in isotonic saline and
stored at 2808C. They were subsequently thawed, lysed in
hypotonic Tris/EDTA buffered at pH 7·4 then centrifuged at
50 000 g for 30min in a Beckman L80 ultracentrifuge. The
resultant pellet was gently resuspended in the buffer and the
fatty acids were extracted, and assayed by flame-ionization
GC (model GC-20A; Shimazdu, Kyoto, Japan). Individual
fatty acids were identified by comparison with known stan-
dards (NuChek Prep Inc., Elysian, MN, USA).
Assessment of fasting serum lipids
Blood samples were also collected in 8ml serum tubes for
determination of TAG, total cholesterol and HDL-cholesterol
(HDL-C) levels using a spectrophotometric autoanalyser
(Konelab, Model 20 £ Ti; Thermo Electron, Waltham, MA,
USA) with the manufacturer’s assay kits, quality controls
and reagents. LDL-cholesterol (LDL-C) was calculated using
the Friedewald Equation(22). Lipid concentrations were aver-
aged from the values for the two blood samples taken at con-
secutive clinic visits.
Statistical analysis
Baseline markers were compared between groups using one-
way ANOVA. CVD risk biomarkers and the DHA content
of erythrocytes were compared between time-points by
repeated measures ANOVA using Statistica for Windows ver-
sion 5.1 (StatSoft Inc., Tulsa, OK, USA). The relationship
between fish oil dose, DHA dose, or changes in erythrocyte
LC n-3 PUFA content and changes in blood lipids (expressed
as a percentage of baseline value) were analysed by linear
regression. All data are expressed as mean with their standard
errors. The level of significance was set at P,0·05.
Results
Seventy-five volunteers commenced the study and sixty-seven
completed. Eight withdrew due to personal time constraints.
There were no significant differences in age, BMI or blood
lipids between the four dosing groups at baseline (Table 1).
BMI was not significantly altered over the 12 weeks with
any of the treatments.
Increases in erythrocyte n-3 PUFA
There was no difference between treatment groups in either
DHA or EPA contents of erythrocytes at baseline. Fish oil
supplementation progressively increased the levels of EPA
and DHA in erythrocyte membranes over 12 weeks (Fig. 1).
The proportion of EPA þ DHA in erythrocytes increased by
up to 80% over 12 weeks. Most of this increase was attribu-
table to DHA which rose by 78% with the 6 g/d of DHA-rich
fish oil. There was a strong linear relationship between the
fish oil dose and the changes in DHA incorporation by week
6 (r 0·71, P,0·001) and week 12 (r 0·72, P,0·001). A
weaker relationship was found between fish oil dose and
change in EPA incorporation at both week 6 (r 0·49,
P,0·001) and week 12 (r 0·58, P,0·001).
Changes in fasting serum lipids
Fish oil supplementation was associated with changes in fast-
ing serum lipids (Fig. 2). A significant group £ time inter-
action was demonstrated for TAG, total cholesterol and
LDL-C. There was no significant group £ time interaction
for HDL-C, nor was there any significant time effect when
the HDL-C data were pooled. TAG did not change signifi-
cantly with the 0 and 2 g/d doses, but was reduced signifi-
cantly after 6 weeks of supplementation with 4 and 6 g/d
and remained low after 12 weeks (Table 1). LDL-C was sig-
nificantly increased at weeks 6 and 12 only with the 4 g/d
dose. HDL-C and total cholesterol did not change significantly
from baseline with any dose. The change in TAG at weeks 6
and 12 was inversely related to baseline TAG concentrations
(week 6, r 20·69, P,0·001; week 12, r 20·44, P,0·001).
There were also significant linear relationships between
DHA intake and changes in fasting blood lipids after 12
weeks of supplementation (Fig. 2).
The changes in blood lipid concentrations were also linearly
related to changes in EPA and DHA incorporation into eryth-
rocytes (Table 2). The reduction in TAG at 12 weeks corre-
lated more strongly with changes in DHA (r 20·38)
than with changes in either EPA (r 20·26) or EPA þ DHA
(r 20·32) after 12 weeks. There was also a relationship
between the increase in erythrocyte DHA after 6 weeks and
TAG reduction after 12 weeks (r 20·44, P,0·001).


















The results of the present study demonstrate that fasting blood
lipid levels can be modified in a dose-dependent fashion by
moderate levels of supplementation with DHA-rich fish oil.
Moreover, beneficial reductions in TAG correlate closely with
early rises in erythrocyteDHA levels. LC n-3 PUFA supplemen-
tation has been reported to lower TAG concentrations by
multiple mechanisms, including by increasing lipoprotein
lipase activity and chylomicron clearance(23), inhibiting hepatic
synthesis, increasing fatty acid oxidation and decreasingVLDL-
cholesterol secretion(24). In the present study, we observed a
dose-related reduction in fasting serum TAG. The greatest
reduction in TAG (26%) occurred after 12 weeks in the group
receiving 6 g/d of fish oil, equivalent to 1·56 g DHA/d. Previous
studies have shown similar reductions in TAG although the
dose of DHA used varied greatly (0·94 to.4 g/d)(9–11).
Previous attempts to define a dose–response between LC
n-3 PUFA consumption and improvements in CVD biomarkers
include multiple dose studies using smaller groups(17–20,25) or
Fig. 1. Dose-dependent effect of DHA-rich fish oil ( , 0; B, 2; , 4; £ , 6 g/d) for 12 weeks on DHA (a) and EPA þ DHA (b) content of erythrocytes (% of total
fatty acids). Values are means with their standard errors depicted by vertical bars. Mean values were significantly different from those of week 0: *P,0·05. Mean
values were significantly different from those of weeks 0 and 6: †P,0·05.
Table 1. Characteristics of the subjects
(Mean values with their standard errors)
Fish oil (g/d)
0 2 4 6
Mean SEM Mean SEM Mean SEM Mean SEM
Age (years) 53 2·3 53 2·0 53 1·3 52 2·1
n 19 17 20 19
No. of males/females 12/7 8/9 11/9 11/8
BMI (kg/m2) 31 1·0 32 1·1 32 1·2 32 1·3
TAG (mmol/l)
Week 0 1·7 0·2 1·7 0·1 2·0 0·3 2·0 0·1
Week 6 1·7 0·2 1·6 0·2 1·6* 0·2 1·5* 0·1
Week 12 1·7 0·2 1·3 0·1 1·7* 0·3 1·4* 0·1
TC (mmol/l)
Week 0 6·6 0·2 6·5 0·2 6·7 0·3 6·1 0·2
Week 6 6·6 0·2 6·8 0·2 7·0 0·3 6·2 0·2
Week 12 6·4 0·3 6·2 0·2 7·0 0·3 6·4 0·2
LDL-C (mmol/l)
Week 0 4·3 0·2 4·4 0·2 4·1 0·2 3·7 0·2
Week 6 4·3 0·2 4·3 0·2 4·5* 0·3 4·0 0·2
Week 12 4·0 0·3 4·0 0·3 4·6* 0·3 4·1 0·2
HDL-C (mmol/l)
Week 0 1·5 0·1 1·5 0·1 1·7 0·1 1·4 0·1
Week 6 1·5 0·1 1·5 0·1 1·7 0·1 1·5 0·1
Week 12 1·5 0·1 1·5 0·1 1·7 0·1 1·6 0·1
HDL-C, fasting serum HDL-cholesterol concentration; LDL-C, fasting serum LDL-cholesterol concentration; TC, fasting
serum total cholesterol concentration.
*Mean values were significantly different from those for 0 g (P,0·05).

















subjects with severe hypertriacylglycerolaemia(17). Moreover,
they have not focused on the role of DHA. In the present
study, LC n-3 PUFA bioavailability was manipulated by low
(2–6 g/d) doses of DHA-rich fish oil, yielding 0·52–1·56 g
DHA/d. Similar intakes could be achieved by eating one serving
of fatty fish such as salmon, mackerel or sardines per day(26). To
reduce the risk of mortality from CVD, a daily intake of 250mg
EPA þ DHA is recommended for healthy individuals and 1 g
for those with CVD(27). Harris & von Schacky(4) previously
showed that the latter (1 g/d) was able to increase erythrocyte
EPA þ DHA levels above 8%, their target value for cardiopro-
tection. An intake of EPA þ DHA of 1·99 g/d in the present
study was able to increase erythrocyte EPA þ DHA levels
to above 8%, possibly providing increased cardioprotection.
Erythrocyte EPA þ DHA content at baseline in the present
study was ,5% of total fatty acids (Fig. 1), which is consist-
ent with previous observations in Australian adults(21,28).
Consuming the 2, 4 and 6 g/d doses of DHA-rich fish oil for
12 weeks increased the proportion of EPA þ DHA in erythro-
cytes to 7·1, 7·9 and 9·0% of total fatty acids, respectively.
Fig. 1 indicates that consumption for a longer duration
approaching the lifespan of erythrocytes (4 months) would
result in some degree of saturation of erythrocyte membranes
so that the linear relationship between dose of fish oil and
level of EPA and DHA in erythrocytes would be weaker.
The difference between doses was more apparent at 6 weeks
than at 12 weeks, suggesting that a maximum level of incor-
poration would ultimately be reached. The intermediate dose
(1·35 g/d of EPA þ DHA) raised erythrocyte EPA þ DHA to
about 8% after 12 weeks, consistent with the observation
that this level can be achieved by long-term supplementation
with about 1 g/d of EPAþDHA(4). The highest dose may be
Fig. 2. Percentage changes in fasting serum lipid concentration from baseline after 6 (B) and 12 (A) weeks of fish oil (DHA) supplementation. Mean values were
significantly different from those of 0 g/d: *P,0·05. —, linear regressions between dose of fish oil (DHA) and changes in lipids after 12 weeks. HDL-C, fasting
serum HDL-cholesterol concentration; LDL-C, fasting serum LDL-cholesterol concentration; TC, fasting serum total cholesterol concentration.
Table 2. Correlations between changes in serum lipids from baseline to












DHA (% of total
fatty acids)
r P r P r P
TC 0·39 0·001 0·41 0·001 0·41 0·001
LDL-C 0·33 0·008 0·35 0·005 0·31 0·014
HDL-C 0·30 0·016 0·30 0·018 0·34 0·006
TAG 20·38 0·002 20·26 0·038 20·32 0·008
HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TC, total cholesterol.

















reaching the upper limit for LC n-3 PUFA incorporation into
erythrocytes. As erythrocyte n-3 PUFA levels reflect changes
in other tissues, including cardiac cells(3), this could explain
the apparent maximum for mortality benefits seen in popu-
lations such as Japan which have a high intake of n-3
PUFA(27).
High levels of LDL-C and low levels of HDL-C are well-
recognized risk factors for the development of atherosclerosis
and CVD(7,29). There were strong linear relationships between
changes in total cholesterol, LDL-C and HDL-C, and increasing
dose of fish oil. The literature has not reported consistent find-
ings in relation to the effect of fish oil supplementation on
cholesterol. No change has been found in total cholesterol
with varying doses of LC n-3 PUFA(8,11,14,30). Fish oil has been
reported to increase total HDL-C(31) or, alternatively, to increase
the HDL2 subfraction without increasing total HDL-C
(28,32).
However, a review of thirty-six crossover and twenty-nine par-
allel design studies concluded that fish oil supplementation has a
minimal effect on HDL-C concentration(33). Others have also
found modest and possibly transient elevations of LDL-C fol-
lowing fish oil supplementation(33). While increases in LDL-C
are generally associated with an increase in CVD risk(34), fish
oil supplementation may have increased LDL particle size
which could offset some of the risk associated with elevated
LDL-C(28,35,36). Increases in LDL-C particle size after fish oil
supplementation have also been negatively correlated with
changes in plasma TAG(37). LDL particle size was not measured
in the present study, so it is not clear how the increase in LDL-C
from fish oil supplementation may influence overall CVD risk
and more research is needed into this area.
The linear relationships between dose of DHA and fasting
serum lipid concentrations outlined in the present study could
be used to predict changes in CVD risk factors which might be
expected after consuming diverse sources of DHA for 12
weeks. For every 1 g/d increase in DHA intake, the present data
would predict a 23% average reduction in TAG, 4·4% increase
in HDL-C and 7·1% increase in LDL-C. However, at 0·5 g/d,
the present data predict virtually no effect on LDL-C
(0·2% reduction), whilst still providing a 13% reduction in TAG.
A potential application of the work described in the present
study would be to predict the effects of consuming DHA-rich
foods on blood lipids and possibly other biomarkers of health
status based on their ability to increase the proportion of DHA
in erythrocytes in healthy subjects over a 6-week period,
rather than having to test the effects of consuming foods on
individual risk factors in long-term studies with appropriate
at-risk subjects, as has previously been the case(21,38,39).
Conclusion
Moderate DHA intakes are related, in a dose-dependent
manner, to incorporation of DHA in erythrocytes and changes
in blood lipids. The close association between incorporation of
DHA in erythrocytes and its effects on serum lipids highlights
the importance of erythrocyte DHA as an indicator of cardio-
vascular health status.
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